Study concept and design: Park, Pieper, Ohman, Harrington, Armstrong, Granger, Jeong, Patel.
Acquisition, analysis, or interpretation of data: Park, Clare, Schulte, Pieper, Shaw, Califf, de Werf, Hirji, Harrington, Jeong, Patel.
Drafting of the manuscript: Park, Clare, Armstrong, Jeong.
Critical revision of the manuscript for important intellectual content: Park, Clare, Schulte, Pieper, Shaw, Califf, Ohman, de Werf, Hirji, Harrington, Granger, Jeong, Patel.
Statistical analysis: Park, Clare, Schulte, Shaw, Jeong.
Obtained funding: Harrington, Jeong.
Administrative, technical, or material support: Park, Califf, Ohman, Harrington, Jeong.
Study supervision: Park, Pieper, de Werf, Hirji, Harrington, Armstrong, Jeong, Patel.
Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Park reported receiving grants from the Cardiovascular Research Foundation (Seoul, Korea) outside this study. Ms Pieper reported receiving personal fees from AstraZeneca and GlaxoSmithKline. Dr Califf reported being a board member of Portola; receiving personal income for serving as a consultant (however, 100% of this income is donated to a non-profit organization) from the following: Novartis, Johnson & Johnson-Scios, Bayer, Roche, Bristol-Myers Squibb, Regeneron, CV Sight, DSI-Lilly, Gambro, Heart.org, Kowa, Genentech, GlaxoSmithKline, Les Laboratories Servier, Amgen, and Regado NJ; receiving research grants or contracts awarded to Duke University, which support his salary, from the following: Amylin, Johnson & Johnson-Scios, Merck/Schering Plough, Novartis, Bristol-Myers Squibb Foundation, and Eli Lilly & Co; receiving income from Portola; and holding equity in N-30 Therapeutics. Dr Harrington reported receiving grant funding from AstraZeneca, Bristol-Myers Squibb, Merck, GlaxoSmithKline, Portola, Regado, The Medicines Company, sanofi-aventis, and Novartis; and receiving personal fees from Merck, The Medicines Company, Amgen, Gilead, Novartis, Medtronic, and MyoKardia. Dr Armstrong reported receiving grant support and personal fees from Boehringer Ingelheim and Merck; receiving personal fees from Eli Lilly, Roche, and AstraZeneca; and grant support from GlaxoSmithKline. Dr Granger reported receiving grant support and personal fees from Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, sanofi-aventis, Takeda, The Medicines Company, AstraZeneca, Daiichi Sankyo, and Janssen Pharmaceuticals; personal fees from Hoffmann-LaRoche, Eli Lilly, Ross Medical Corporation, Salix Pharmaceuticals, and Gilead; and grant support from Medtronic Foundation, Merck, and Bayer. Dr Patel reported serving as a consultant to Bayer; receiving grant support from Johnson & Johnson, the National Heart, Lung, and Blood Institute, the Agency for Healthcare Quality, AstraZeneca, and GlaxoSmithKline; and serving on advisory boards for Genzyme, Janssen, Otsuka, and AstraZeneca. No other disclosures were reported.
Funding/Support: This study was supported in part by the John Bush Simson Fund (awarded to Dr Patel). The statistical portion of the manuscript was funded by the Duke Clinical Research Institute.
Role of the Funders/Sponsors: The John Bush Simson Fund and the Duke Clinical Research Institute had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
A full list of study investigators and coordinators for each trial has been published previously.11- 18